A randomized phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 7275-7283

  Garon, Edward B ^a   Neidhart, Jeffrey D ^b   Gabrail, Nashat Y ^c   de Oliveira, Moacyr R ^d   Balkissoon, Jai ^e   Kabbinavar, Fairooz ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b San Juan Oncology Associates   (United States)

^c Gabrail Cancer Center   (United States)

^d Northwest Medical Specialties   (United States)

^e Pharmaceutical Product Development   (United States)

Author keywords

Bevacizumab; CA4P; Carboplatin; NSCLC; Paclitaxel

Indexed keywords

AMLODIPINE; BEVACIZUMAB; CARBOPLATIN; COMBRETASTATIN A4 PHOSPHATE; DEXAMETHASONE; DILTIAZEM; PACLITAXEL; PARACETAMOL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BACKACHE; BRADYCARDIA; CANCER STAGING; CANCER SURVIVAL; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; EAR DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPERTENSION; HYPESTHESIA; HYPONATREMIA; INNER EAR DISEASE; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MENTAL DISEASE; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYALGIA; NEOPLASM; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PHYSICAL ACTIVITY; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SOFT TISSUE DISEASE; STOMATITIS; TACHYCARDIA; THORAX DISEASE; THORAX PAIN; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VASCULAR DISEASE;

EID: 85006043194     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S109186     Document Type: Article

References (33)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1): 5-29.
2. American Cancer Society. What is non-small cell lung cancer? Available from: http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer. Accessed January 4, 2016.
3. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015; 373(2): 123-135.
4. Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21): 2018-2028.
5. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10): 947-957.
6. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23): 2167-2177.
7. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971; 133(2): 275-288.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24): 2542-2550.
9. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014; 384(9944): 665-673.
10. Mok TS, Loong HH. A REVELation in non-small-cell lung cancer treatment? Lancet. 2014; 384(9944): 640-642.
11. Prise VE, Honess DJ, Stratford MR, Wilson J, Tozer GM. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol. 2002; 21(4): 717-726.
12. Rini BI, Garcia JA, Cooney MM, et al. A phase I study of sunitinib plus bevacizumab in advanced solid tumors. Clin Cancer Res. 2009; 15(19): 6277-6283.
13. Das M, Wakelee H. Vascular disrupting agents. J Thorac Oncol. 2010; 5(12 Suppl 6): S482-S483.
14. Gridelli C, Rossi A, Maione P, et al. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist. 2009; 14(6): 612-620.
15. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer. 2008; 99(12): 2006-2012.
16. Lara PN Jr, Douillard JY, Nakagawa K, et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol. 2011; 29(22): 2965-2971.
17. Mazzone P, Mekhail T. Current and emerging medical treatments for non-small cell lung cancer: a primer for pulmonologists. Respir Med. 2012; 106(4): 473-492.
18. National Institutes of Health. A study of ASA404 or placebo in combination with docetaxel in second-line treatment for (stage IIIb/IV) non-small cell lung cancer (ATTRACT-2). Available from: https://clinicaltrials.gov/ct2/show/study/NCT00738387?term=ASA404&rank=11. Accessed January 4, 2016.
19. Landuyt W, Verdoes O, Darius DO, et al. Vascular targeting of solid tumours: a major ‘inverse’ volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer. 2000; 36(14): 1833-1843.
20. Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys. 2005; 62(3): 846-853.
21. Sosa JA, Elisei R, Jarzab B, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014; 24(2): 232-240.
22. Monk BJ, Sill MW, Walker JL, et al. Randomized phase II evaluation of bevacizumab versus bevacizumab plus fosbretabulin in recurrent ovarian, tubal, or peritoneal carcinoma: an NRG oncology/gynecologic oncology group study. J Clin Oncol. 2016; 34(19): 2279-2286.
23. Pettit GR, Singh SB, Niven ML, Hamel E, Schmidt JM. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod. 1987; 50(1): 119-131.
24. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002; 62(12): 3408-3416.
25. Rustin GJS, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 2003; 21(15): 2815-2822.
26. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol. 2003; 21(23): 4428-4438.
27. Nathan P, Zweifel M, Padhani AR, et al. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2012; 18(12): 3428-3439.
28. Rustin GJ, Shreeves G, Nathan PD, et al. A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer. 2010; 102(9): 1355-1360.
29. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 2008; 28(4B): 2027-2031.
30. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science. 2006; 313(5794): 1785-1787.
31. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45(2): 228-247.
32. Ke Q, Bodyak N, Rigor DL, Hurst NW, Chaplin DJ, Kang PM. Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats. Vascul Pharmacol. 2009; 51(5-6): 337-343.
33. Ke Q, Samad MA, Bae S, Chaplin DJ, Kang PM. Exaggerated hypertensive response to combretastatin A-4 phosphate in hypertensive rats: effective pharmacological inhibition by diltiazem. Vascul Pharmacol. 2015; 74: 73-79.